PERCF (Percheron Therapeutics) Book Value per Share: $0.00 (As of Dec. 2025)


What is Percheron Therapeutics Book Value per Share?

Percheron Therapeutics PERCF -0.18% Book Value per Share is $0.00 as of Dec. 2025. The stock has 2 warning signs investors should review.

Percheron Therapeutics's book value per share for the quarter that ended in Dec. 2025 was $0.00.

During the past 12 months, Percheron Therapeutics's average Book Value Per Share Growth Rate was -57.10% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -33.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -2.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -6.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Percheron Therapeutics was 64.20% per year. The lowest was -42.10% per year. And the median was -15.45% per year.

Percheron Therapeutics's current price is $0.00283. Its book value per share for the quarter that ended in Dec. 2025 was $0.00. Hence, today's PB Ratio of Percheron Therapeutics is 0.47.

During the past 13 years, the highest P/B Ratio of Percheron Therapeutics was 11.48. The lowest was 0.15. And the median was 1.96.

Warning Sign:

Percheron Therapeutics Ltd stock PB Ratio (=0.67) is close to 1-year high of 0.67.


Percheron Therapeutics  (OTCPK:PERCF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Percheron Therapeutics Book Value per Share Related Terms


Percheron Therapeutics Book Value per Share Historical Data

* Premium members only.

The historical data trend for Percheron Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics Book Value per Share Chart

Percheron Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.02 0.01 0.01 0.01

Percheron Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.00

PERCF vs ZTS, UTHR: Book Value per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Percheron Therapeutics PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Percheron Therapeutics's PB Ratio falls into.



Percheron Therapeutics Book Value per Share Calculation

Percheron Therapeutics's Book Value Per Share for the fiscal year that ended in Jun. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(6.51-0.00)/1,116.44
=0.01

Percheron Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2025 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(4.74-0.00)/1,116.44
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $0.00 mean?
Percheron Therapeutics (PERCF) has a Book Value per Share of $0.00 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Percheron Therapeutics and its competitors.
Is Percheron Therapeutics' Book Value per Share too high?
Percheron Therapeutics' current Book Value per Share is $0.00.
How does Percheron Therapeutics' Book Value per Share compare to ZTS and UTHR?
Percheron Therapeutics' Book Value per Share of $0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Percheron Therapeutics and its competitors. Percheron Therapeutics's current Book Value per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Book Value per Share of $0.00. The current Book Value per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Book Value per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Percheron Therapeutics Business Description

Other Exchanges AWY0:GermanyPER:Australia
Address 35 Collins Street, Level 30, Collins Place, Melbourne, VIC, AUS, 3000
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.